Locus-Specific Mutation Databases for Neurodegenerative
Marc Cruts,1,2∗Jessie Theuns,1,2and Christine Van Broeckhoven1,2
1Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerpen, Belgium;2Laboratory of Neurogenetics, Institute
Born-Bunge, University of Antwerp, Antwerpen, Belgium
For the Databases in Neurogenetics Special Issue
Received 13 February 2012; accepted revised manuscript 26 April 2012.
Published online 11 May 2012 in Wiley Online Library (www.wiley.com/humanmutation).DOI: 10.1002/humu.22117
ABSTRACT: The Alzheimer disease and frontotemporal
dementia (AD&FTLD) and Parkinson disease (PD) Mu-
tation Databases make available curated information of
sequence variations in genes causing Mendelian forms of
the most common neurodegenerative brain disease AD,
are established resources for clinical geneticists, neurolo-
gists, and researchers in need of comprehensive, refer-
enced genetic, epidemiologic, clinical, neuropathological,
and/or cell biological information of specific gene muta-
tions in these diseases. In addition, the aggregate analy-
sis of all information available in the databases provides
unique opportunities to extract mutation characteristics
and genotype–phenotype correlations, which would be
otherwise unnoticed and unexplored. Such analyses re-
vealed that 61.4% of mutations are private to one single
family, while only 5.7% of mutations occur in 10 or more
families. The five mutations with most frequent indepen-
48% of PD families recorded in the Mutation Databases,
respectively. Although these figures are inevitably biased
ably also reflect the occurrence of multiple rare and few
relatively common mutations in the inherited forms of
these diseases. Finally, with the exception of the PD genes
PARK2 and PINK1, all other genes are associated with
more than one clinical diagnosis or characteristics thereof.
Hum Mutat 33:1340–1344, 2012.C ?2012 Wiley Periodicals, Inc.
KEY WORDS: locus-specific; mutation database; neurode-
generative brain disease; Alzheimer disease; frontotempo-
ral lobar degeneration; Parkinson disease
∗Correspondence to: Marc Cruts, Neurodegenerative Brain Diseases Group, VIB
Department of Molecular Genetics, University of Antwerp - CDE, Universiteitsplein 1,
B-2610, Antwerp, Belgium; E-mail: firstname.lastname@example.org
Contract grant sponsor: Interuniversity Attraction Poles Programme IAP P6/43 of
the Belgian Science Policy Office; Methusalem program of the Flemish Government;
Foundation for Alzheimer Research (SAO/FRMA); Queen Elisabeth Medical Foundation
(QEMF); Research Foundation—Flanders (FWO); Agency for Innovation by Science
Neurodegenerative brain diseases are adult-onset diseases in
which degeneration of specific neuronal populations of the central
erative brain diseases are Alzheimer disease (AD; MIM# 104300),
Parkinson disease (PD; MIM# 168600), and frontotemporal lobar
increasing in the absence of effective therapies. AD, PD, and FTLD
are proteinopathies in which the toxic aggregation and deposition
of characteristic proteins in specific brain areas are major etiologic
and diagnostic hallmarks [Yankner et al., 2008]. Genetics plays a
major role in all three diseases, which in general result from a com-
plex combination of multiple genetic risk and protective factors, in
concert withenvironmental factors constitutinganindividual’s risk
to develop the disease at a given point in life. However, AD, FTLD,
as well as PD have an infrequent monogenic component in which
a highly penetrant Mendelian inherited dominant or recessive mu-
tation invariantly leads to disease, be it often at variable and largely
Knowledge of monogenic mutations leading to neurodegenera-
tive brain diseases is of great value for several reasons. In clinical
genetic counseling, for example, knowledge of pathological mu-
tations and their genic location will assist in working out efficient
is used to support or specify a clinical diagnosis, a quick survey of
parameters such as evidence of familial cosegregation, frequencies
of occurrence in patients and unaffected individuals, interspecies
codon conservation, cell biological consequences, and genotype–
tic decision prior to treatment. In a research setting, knowledge of
disease gene might reveal valuable indications towards functionally
critical protein domains and/or motifs and disease mechanisms.
The AD&FTLD and PD Mutation Databases described in this
manuscript aim to provide this information for the most com-
monly mutated genes in a comprehensive way. The AD&FTLD
Mutation Database is a locus-specific database (LSDB) that was
conceived in 1998 [Cruts and Van Broeckhoven, 1998b] in the per-
initiative originally fostered by the Human Genome Organization
(www.hugo-international.org) that has through the years evolved
to the Human Genome Variation Society (HGVS, www.hgvs.org).
mentation, and free distribution of genomic variation information
and associated clinical variations. From the start, the AD&FTLD
Mutation Database stores curated genetic, clinical, and biological
information of DNA variations in the Mendelian AD genes APP,
C ?2012 WILEY PERIODICALS, INC.
Table 1. Genes Catalogued in the AD&FTLD and PD Mutation
Total 14 614/296/2303,5791,127
aJournal article or personal communication.
PSEN1, and PSEN2 (Table 1) [Cruts and Van Broeckhoven, 1998a].
Because of observed genetic overlaps between the etiology of both,
AD and FTLD, all known Mendelian FTLD genes (Table 1) were
added to the AD&FTLD Mutation Database from 2004 onward
[Gijselinck et al., 2008; Rademakers et al., 2004]. The PD Muta-
tion Database was set up in 2010 [Nuytemans et al., 2010], es-
sentially in response to the lack of comprehensive LSDBs of PD
genes. Today, it contains extended genetic and clinical informa-
tion of variations in the five most common Mendelian PD genes
(Table 1). The primary user interfaces of the databases are publicly
accessible dedicated websites: www.molgen.ua.ac.be/ADMutations
and www.molgen.ua.ac.be/FTDMutations for the AD&FTLD Mu-
tation Database, and www.molgen.ua.ac.be/PDmutDB for the PD
mutations database. In addition, basic genetic information of the
mutations is shared with the Gen2Phen project [Webb et al., 2011]
and NCBI’s dbSNP [Sayers et al., 2012].
Variation Inclusion Policy
The AD&FTLD and PD Mutation Databases aim to provide an
up to date catalogue of all gene variations linked to disease causa-
tion or predicted to affect the encoded protein sequence. Because
the knowledge of benign coding variations is as important as the
knowledge of clinical variations, these are also documented. Non-
coding neutral variations are excluded because in most genes they
outnumber coding variations and (1) are not the main interest of
dard exon-based mutation screening strategies, and (3) are rarely
documented in detail in literature reports, the major resource of
the database content. As a result, comprehensively cataloging these
against other variation databases such as NCBI’s dbSNP, that are
much better placed to catalog large numbers of this type of varia-
tions, makes little sense. For example, dbSNP build 135 holds 3,654
common variations in the human FTLD-associated gene MAPT
[Cruts et al., 2005]. Most of these variations are located deeply in
introns, while the 43 known clinical mutations are in coding re-
gions of exons 1, and 9–13, and the first 19 nucleotides of intron
10 [Rademakers et al., 2004]. Information of common variations
outside these genic regions is not of direct interest to the clini-
cal and molecular geneticists consulting the AD&FTLD Mutation
Database. Obviously, common variations associated with disease
susceptibility are stored in separate, dedicated databases specialized
to hold other descriptive parameters [Lill and Bertram, 2012]), for
example, AlzGene [Bertram et al., 2007], and PDGene [Lill et al.,
Genes currently included in the AD&FTLD and PD Mutation
Databases are shown in Table 1. Repeat expansion mutations pose
expansions of the noncoding G4C2repeat in the C9orf72 promoter
ered the same mutation. The PD Mutation Database contains gene
Next to personal communications (<1%), scientific literature
(>99%) is the major data source. The NCBI PubMed literature
database is periodically scanned using as query the genes’ offi-
cial symbols and full names as designated by the Human Gene
Nomenclature Committee [Seal et al., 2011], complemented with
all gene aliases listed in the NCBI Gene database or commonly used
in literature. Retrieved publications are scanned for the presence
of information on gene variations. Variation names are checked
for consistency with the current HGVS guidelines for descrip-
tion of sequence variations [den Dunnen and Antonarakis, 2000]
(www.hgvs.org/mutnomen). Because ambiguous variation names
are not uncommon in literature, reliability criteria are employed
to evaluate the genuineness of the described variation. Variations
consistently described following two or more naming systems, for
the publication is searched for other evidence, for example, a DNA
variation remains ambiguous, the authors are contacted. To main-
tain database content integrity, variations that remain ambiguous
Genetic and Clinical Documentation
Variations are stored in the databases with names according to
the HGVS guidelines, but commonly used aliases are also given.
Variant description is shown at the level of gene, transcript, and
protein, indicating the affected region and whether the variation is
indirect evidence, for example, a predicted protein variation based
on a transcript sequence and codon translation table. Variation
position numbering is relative to stable RefSeq reference sequences
[Pruitt et al., 2009] for gene (RefSeqGene), RNA, and protein. For
historical reasons, genomic numbering is also given relative to non-
RefSeqGene sequences for some genes. Mutalyzer [Wildeman et al.,
2008] is used to assist in generating or verifying variation names.
All details are documented with a comprehensive list of literature
neuropathological confirmation of the diagnosis are also recorded
for each documented family member. Availability of these details
of each individual within pedigrees is useful to form an opinion
of cosegregation and penetrance of a variation with respect to zy-
gosity. In contrast to the PD Mutation Database, in the AD&FTLD
Mutation Database, all information is stored at the level of the
HUMAN MUTATION, Vol. 33, No. 9, 1340–1344, 2012
family, including family averages and ranges of clinical parameters
such as ages at onset and death.
Together, the wealth of information stored in the AD&FTLD
and PD Mutation Databases have revealed interesting observations.
that as much as 60–64% of clinical variations are private to one sin-
occur in 10 or more families. It should be noted that literature is in-
evitably biased toward novel mutations because publishing known
mutations is hindered by the limited degree of novelty and un-
derestimated informative value. Moreover, an unknown number of
mutations identified in molecular diagnostic environments where
publishing is not a priority never reaches the public domain. These
biases are reflected in the data available in the Mutation Databases
and consequently, private mutations are most probably overesti-
mated. However, at least these data suggest that the genetic basis of
screening strategies aiming to detect only known mutations have
limited value. Oppositely few relatively common mutations do ex-
ist: the five mutations with the highest number of independent
observations for each disease are reported in 21% of AD, 43% of
mutation, which in itself explains 34% of all PD families. The high
relative occurrence of some variations is explained by a founder ef-
of specific variations and the identification of population-specific
founder mutations. On the basis of this information, it is advised to
work out region-specific gene and exon screening priorities.
It is apparent that all AD, FTLD, and PD genes are associated
with a wide-onset age range, although Mendelian mutations are on
average associated with a disease onset before the age of 65 years
(Fig. 1). PARK7 mutations are associated with onset ages of PD in
two families only, in which patients carry a homozygous mutation
recorded in PSEN1 mutation carriers, in whom the disease starts
on average 8.4 years earlier than in APP mutation carriers (average
42.9 vs. 51.3 years) and 14.2 years earlier than in PSEN2 mutation
carriers (average 57.1 years) (Fig. 1). In FTLD, the earliest aver-
age onset age is associated with MAPT (47.9 years) and VCP (49.5
years) mutations. Intermediate onset ages of an average 55 years are
noted in FTLD patients with a C9orf72 expanded hexanucleotide
repeat. GRN mutations are associated with an average onset age of
59.3 years, and CHMP2B mutations with 64.8 years. Homozygous
or compound heterozygous PARK2 and PARK7 may cause juvenile
onset of PD with average onset ages of 31.2 and 31.3 years, respec-
tively. Onset age in SNCA mutation carriers is on average 15.6 years
later (average 46.9 years), while LRRK2 mutation carriers have on
average the latest onset age (55.2 years) (Fig. 1). Importantly, in all
three diseases, even interquartile onset age ranges overlap substan-
tially among all genes, meaning that onset age is not an absolute
discriminator of mutant gene (Fig. 1).
When considering the correlation between primary clinical diag-
noses and mutant gene, each gene is strongly associated with one
clinical diagnosis (Table 2). However, genetic overlaps between the
different neurodegenerative brain diseases and the clinical scope
of each gene are significant. PSEN1 and 2, MAPT, and GRN muta-
and/or PD in a substantial number of patients (Table 2). Strikingly,
Family-based average onset ages of established pathogenic variants
were used. For PARK7, PARK2, and PINK1, only patients carrying ho-
mozygous or compound heterozygous mutations were included in the
calculations. Boxes represent the interquartile onset age distribution,
horizontal lines indicate medians, whiskers show standard deviations,
and circles indicate outliers.
Boxplot showing disease onset age distributions per gene.
all genes have been associated with clinical characteristics of PD,
with the exception of FTLD genes C9ORF72, VCP, and CHMP2B
(Table 2). These latter genes however were in addition to FTLD also
associated with ALS, inclusion body myopathy, and Paget disease.
PINK1 and PARK2 mutations appear specific of a clinical diagnosis
of PD; however, PARK2 mutations have also been associated with
dopa-responsive dystonia [Clot et al., 2009].
Taken together, the AD&FTLD and PD Mutation Databases are
useful tools to work out a gene and exon priority scheme for muta-
tion screening, for example, in the context of clinical genetic coun-
seling. As illustrated above, parameters to be taken into account are
clinical diagnosis, onset age, family history, and regional mutation
ease, a mutation cannot formally be excluded from patients with a
late-onset age above 65 years, or patients without noted family his-
occurrence of Mendelian mutations is low due to the high number
of patients with a complex non-Mendelian disease etiology.
Effect on Protein Function
Consequences of the mutation on gene function are included
in the Mutation Databases as far as their relevance to the disease
disease mechanism is the amyloid β cascade [Hardy, 2006], which
states that the relative increase of Aβ42production is at the basis
of AD biology. Mutations in the Aβ precursor APP or the pro-
teases PSEN1 and PSEN2 play established roles in Aβ production
[Hardy, 1997]. Therefore, in vivo and in vitro evidence of the effect
of AD mutations on Aβ production is recorded in the AD&FTLD
Mutation Database [Theuns et al., 2006]. Similarly, established bi-
ological consequences of MAPT mutations are their effect on ex-
pression of 4R/3R tau protein ratio, microtubule assembly, and
tau filament formation [Rademakers et al., 2004] and experimental
HUMAN MUTATION, Vol. 33, No. 9, 1340–1344, 2012
Table 2. Clinical Presentation Associated with Each Disease Gene
LRRK2PINK1 PARK2SNCAPARK7 APPPSEN1PSEN2MAPT GRNVCP CHMP2BC9orf72
97% 93%60% 29%
Shown are percentages of independent observations of mutations in a given gene that are associated with clinical characteristics that are typical of the respective primary
diagnosis. Primary diagnoses other than PD, AD, or FTLD (e.g., ALS) are not shown but were included in the calculations.
of the homohexameric protein organization (PDB entry 3CF3). Mutations are shown as red atoms on the ribbon presentation of the CDC48-like
N-terminal domain (yellow), and D1 (blue) and D2 (green) ATPase domains, clearly demonstrating the alignment of mutations at the interface
between the CDC48 and D1 domains [Weihl et al., 2009].
data in this context are also included in the AD&FTLD Mutation
When the disease mechanism is not well known or the role of
genes and mutations in the biology of disease is not established, the
location of the variation in the protein and its predicted effect on
protein function are useful indicators. Therefore, two-dimensional
(2D) and/or three-dimensional (3D) graphic protein presentations
showing the variation position with respect to protein domain
are provided in the Mutation Databases. For example, all known
pathogenic APP mutations are located at one of three secretase sites
or inside the Aβ peptide sequence and affect Aβ production or
aggregation properties, respectively [Brouwers et al., 2008], which
can be appreciated from the provided 2D protein mutation map.
Similarly, all known pathogenic VCP mutations are located at the
interface between the N-terminal CDC48-like domain and the D1
ATPase domain [Weihl et al., 2009], resulting in reduced affinity for
ADP [Tang et al., 2010]. Therefore, even though the exact role of
tion is useful to predict pathogenecity and can only be appreciated
from the 3D structural map provided in the AD&FTLD Mutation
Database (Fig. 2).
For similar reasons, the Mutation Databases also provide the op-
tion to show an overview of the mutations as a custom track in the
offering the benefit to interpret the location of mutations relative
to the host of available genomic annotation tracks, like amino acid
The AD&FTLD and PD Mutation Databases are established re-
sources for clinical geneticists, neurologists, and researchers alike
HUMAN MUTATION, Vol. 33, No. 9, 1340–1344, 2012
receiving a steadily increasing number of independent visits each Download full-text
keep the content of the databases up to date and direct submissions
are encouraged to also include unpublished variants. Database in-
clusion of the more recently identified PD genes ATP13A2, EIF4G1,
FBXO7, GBA, GIGYF2, HTRA2, VPS35, and UCHL1 is planned.
The AD&FTLD Mutation Database was designed to hold dom-
inant, heterozygous mutations only, preventing the allocation of
multiple variations to one family, for example, recessive mutations
such as the homozygous APP p.Ala673Val mutation affecting Aβ
strictly defined patient series. A major database improvement will
be the merging of the AD&FTLD and the PD Mutation Databases,
facilitating the storage of recessive mutations for AD and FTLD
as is already the case for PD. Also with the upcoming naturaliza-
tion of next-generation sequencing technologies, multigenic causes
of disease will probably be revealed and the structure of Mutation
Databases is being prepared for that. Importantly, this unified mu-
tation database for the major neurodegenerative brain diseases will
better accommodate the clinicogenetic overlaps between PD, AD,
and FTLD. Also, in this respect, further improvement of the im-
plementation of clinical data and genotype–phenotype correlates
will be established by the implementation of phenotypic ontology
[K¨ ohler et al., 2012], allowing to associate genetic variations with
specific clinical characteristics rather than disease diagnoses.
Finally, defining pathogenic nature of a variation is not a trivial
issue and specifying general criteria is a matter of much debate. For
mutations in the AD genes APP, PSEN1, and PSEN2, an algorithm
has been proposed, primarily based on segregation information
and effect on Aβ processing [Guerreiro et al., 2010]. In more gen-
in vivo biochemical readouts are unavailable. Especially in the case
of recessive disease genes, segregation evidence is rarely obtained
in adult-onset diseases. Deployment of a transparent probability
estimation system of the pathogenic nature of a variation based on
generative disorder, location within the protein, interspecies amino
acid conservation, in vitro and in vivo evidence and predicted vari-
ation characteristics is being developed.
Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. 2007. Systematic meta-
analyses of Alzheimer disease genetic association studies: the AlzGene database.
Nat Genet 39:17–23.
Brouwers N, Sleegers K, Van Broeckhoven C. 2008. Molecular genetics of Alzheimer’s
disease: an update. Ann Med 40:562–583.
Clot F, Grabli D, Cazeneuve C, Roze E, Castelnau P, Chabrol B, Landrieu P, Nguyen
K, Ponsot G, Abada M, Doummar D, Damier P, et al. 2009. Exhaustive analysis of
Cotton RG, McKusick V, Scriver CR. 1998. The HUGO Mutation Database initiative.
Cruts M, Rademakers R, Gijselinck I, van der Zee J, Dermaut B, De Pooter T, De Rijk
P, Del Favero J, Van Broeckhoven C. 2005. Genomic architecture of human 17q21
linked to frontotemporal dementia uncovers a highly homologous family of low
copy repeats in the tau region. Hum Mol Genet 14:1753–1762.
Cruts M, Van Broeckhoven C. 1998a. Molecular genetics of Alzheimer’s disease. Ann
denDunnen JT,AntonarakisSE.2000.Mutation nomenclature extensionsandsugges-
tions to describe complex mutations: a discussion. Hum Mutat 15:7–12.
APP gene with dominant-negative effect on amyloidogenesis. Science 323:1473–
Gijselinck I, Van Broeckhoven C, Cruts M. 2008. Granulin mutations associated with
frontotemporal lobar degeneration and related disorders: an update. Hum Mutat
Guerreiro RJ, Baquero M, Blesa R, Boada M, Bras JM, Bullido MJ, Calado A, Crook R,
Ferreira C, Frank A, Gomez-Isla T, Hernandez I, et al. 2010. Genetic screening of
Alzheimer’s disease genes in Iberian and African samples yields novel mutations
in presenilins and APP. Neurobiol Aging 31:725–731.
Hardy J. 1997. Amyloid, the presenilins and Alzheimer’s disease. Trends Neurosci
Hardy J. 2006. Alzheimer’s disease: the amyloid cascade hypothesis: an update and
reappraisal. J Alzheimers Dis 9:151–153.
K¨ ohler S, Doelken S, Rath A, Ayme S, Robinson P. 2012. Ontological phenotype
standards for neurogenetics. Hum Mutat.
Lill CM, Bertram L. 2012. Developing the “next generation” of genetic association
databases for complex diseases. Hum Mutat.
Lill CM, Roehr JT, McQueen MB, Kavvoura FK, Bagade S, Schjeide BM, Schjeide LM,
Meissner E, Zauft U, Allen NC, Liu T, Schilling M, et al; 23andMe, The Genetic
Epidemiology of Parkinson’s Disease Consortium; The International Parkinson’s
Disease Genomics Consortium; The Parkinson’s Disease GWAS Consortium; The
Wellcome Trust Case Control Consortium 2. 2012. Comprehensive research syn-
opsis and systematic meta-analyses in parkinson’s disease genetics: the PDGene
database. PLoS Genet 8:e1002548.
Martindale J, Seneca S, Wieczorek S, Sequeiros J. 2012. Challenges associated with ge-
ataxias. Hum Mutat.
Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C. 2010. Genetic etiology of
and LRRK2 genes: a mutation update. Hum Mutat 31:763–780.
Pruitt KD, Tatusova T, Klimke W, Maglott DR. 2009. NCBI Reference Sequences:
current status, policy and new initiatives. Nucleic Acids Res 37:D32–D36.
Rademakers R, Cruts M, Van Broeckhoven C. 2004. The role of tau (MAPT) in fron-
totemporal dementia and related tauopathies. Hum Mutat 24:277–295.
DM, Dicuccio M, Federhen S, Feolo M, Fingerman IM, et al. 2012. Database
resources of the national center for biotechnology information. Nucleic Acids Res
Seal RL, Gordon SM, Lush MJ, Wright MW, Bruford EA. 2011. genenames.org: the
HGNC resources in 2011. Nucleic Acids Res 39:D514–D519.
Tang WK, Li D, Li CC, Esser L, Dai R, Guo L, Xia D. 2010. A novel ATP-dependent
conformation in p97 N-D1 fragment revealed by crystal structures of disease-
related mutants. EMBO J. 29:2217–2229
Theuns J, Marjaux E, Vandenbulcke M, Van Laere K, Kumar-Singh S, Bormans G,
Brouwers N, Van den Broeck M, Vennekens K, Corsmit E, Cruts M, De Strooper
B, Van Broeckhoven C, Vandenberghe R. 2006. Alzheimer dementia caused by
a novel mutation located in the APP C-terminal intracytosolic fragment. Hum
Webb AJ, Thorisson GA, Brookes AJ;GEN2PHEN Consortium. 2011. An informat-
ics project and online “Knowledge Centre” supporting modern genotype-to-
phenotype research. Hum Mutat 32:543–550.
body myopathy with Paget’s disease of the bone and fronto-temporal dementia.
Neuromuscular Disorders 19:308–315.
descriptions in Mutation Databases and literature using the Mutalyzer sequence
variation nomenclature checker. Hum Mutat 29:6–13.
Yankner BA, Lu T, Loerch P. 2008. The aging brain. Annu Rev Pathol 3:41–66.
HUMAN MUTATION, Vol. 33, No. 9, 1340–1344, 2012